Browse the evidence

Metabolic drugs such as GLP-1-based therapies and SGLT2 inhibitors have benefits that extend beyond metabolic improvements into changes in chronic inflammation.

Practitioners should consider the anti-inflammatory potential of metabolic drugs in clinical settings.

The review discusses emerging therapeutic strategies for MASLD and its associated comorbidities.

Practitioners should stay informed about new treatment options for MASLD and its comorbidities.

Pharmacological classes of metabolic drugs have unexpected and often beneficial effects on cardiovascular outcomes.

Consider the use of metabolic drugs in managing cardiovascular health.

A maladaptive adipokine milieu is associated with endothelial dysfunction, myocardial stiffening, and muscle atrophy in HFpEF.

Recognizing this cycle can inform targeted interventions.

Small molecule agonists of GLP-1 receptor have advantages of low cost and oral administration compared to peptide drugs.

Practitioners may consider small molecule GLP-1 receptor agonists as a cost-effective and convenient treatment option.

Several classes of medications have been explored to target different pathways and receptors to preserve lean body mass during weight loss.

Practitioners may consider pharmacological options to help preserve muscle mass during weight loss.

Recent progress in glucose-responsive systems enables real-time, glucose-triggered therapeutic activation.

This technology could lead to more effective and responsive diabetes treatments.

Recent advancements in anti-obesity drugs allow for genotype-informed treatment options.

Practitioners can utilize genetic information to tailor obesity treatments.

One standard deviation higher polygenic score (PS) related to smaller one-year change in waist circumference adjusted for body mass index (WCadjBMI) in the lifestyle intervention arms at year 1, predicting poorer response among White participants overall.

Practitioners should consider genetic factors when assessing weight loss responses to lifestyle interventions.

Participants assigned a plant-based diet for phase 1 did not see an increase in TMAO during their subsequent animal-meat phase.

Dietary sequencing may influence TMAO levels and cardiovascular risk.

Around 50 significant metabolites and 12 significant microbiota genera correlated with TMAO.

Understanding these correlations may help in developing targeted therapies for CVD prevention.

Adipositas is influenced by environmental factors and genetic variants.

Understanding the dual influence of genetics and environment can guide obesity treatment strategies.

Orlistat's peak concentration stayed below 5 ng/mL, indicating minimal systemic absorption.

The low systemic absorption suggests a reduced risk of systemic side effects from orlistat.

Dual agonists provide additive and potentially synergistic metabolic benefits through complementary receptor activation.

Practitioners may explore the use of dual agonists for enhanced metabolic outcomes in patients.

Tirzepatide improves β-cell function in T2D patients by reprogramming stressed β cells and restoring β-cell identity through FOXO1-dependent transcriptional reactivation.

Practitioners may consider tirzepatide as a therapeutic option for improving β-cell function in T2D patients.

Emerging therapeutic approaches aim to engage multiple bioenergetic pathways to restore metabolic equilibrium.

Practitioners should consider multi-target approaches in developing treatments for metabolic dysfunction.

The gut microbiome may contribute to the development of obesity in humans.

Practitioners should consider the gut microbiome as a potential factor in obesity management.

The decision tree yields an AUC of 0.898 for phenotyping PCOS.

Clinicians can utilize this decision tree for effective phenotyping of PCOS.

The decision tree aims to improve PCOS management by reducing multiple blood tests and physician workload.

This decision tree could streamline the diagnostic process for PCOS, making it more efficient for healthcare providers.

The amino acid profile of bread with 5% WSF is higher than that of the control bread.

Using WSF can enhance the amino acid content of bread, beneficial for nutrition.

Compounds K2 and K5 decreased and maintained the body weight of diet-induced obese mice.

Compounds K2 and K5 may be potential candidates for drug development targeting obesity.

The study proposes an approach for treating overweight and obese patients by preventing or reducing CCK1 activation.

This approach may inform future obesity treatments focusing on CCK1 regulation.

Adipose tissue browning is linked to improved metabolic and cardiovascular health.

Promoting adipose tissue browning may enhance metabolic and cardiovascular health.

White adipose tissue browning mitigates inflammation and improves cardiometabolic health.

Encouraging white adipose tissue browning may reduce inflammation and enhance cardiometabolic health.